Peptides for Fat Loss: What the Evidence Shows

Search for fat-loss peptides and you get two very different groups of compounds presented as one category. Separating them is the single most useful thing anyone can do before evaluating any of them.

This is an educational overview, not medical advice, and several compounds below are unapproved research chemicals rather than products anyone should be taking.

Which peptides actually cause fat loss?

Graded on weight loss specifically, the evidence sorts cleanly — and not in the direction the marketing suggests.

Compound	Grade	Status
Semaglutide	A	FDA-approved
Tirzepatide	A	FDA-approved
Liraglutide	A	FDA-approved
Tesamorelin	A (visceral fat, HIV lipodystrophy)	FDA-approved
Cagrilintide	B	Investigational
Orforglipron	B	FDA-approved
Retatrutide	C	Investigational
CJC-1295	U	Research chemical
Ipamorelin	U	Research chemical
GHRP-2	E	Research chemical
GHRP-6	E	Research chemical

Every peptide with Grade A evidence for fat loss is an approved medication. Every compound sold as a “fat loss peptide” on the research-chemical market is graded U or E.

That is not a coincidence. Grade A requires large controlled human trials, and running those is what turns a compound into an approved drug.

Why do the approved ones work?

They act on appetite regulation rather than on fat tissue directly.

Semaglutide is a GLP-1 receptor agonist; tirzepatide adds GIP. Both slow gastric emptying and reduce appetite through central pathways, and the weight loss follows from eating less. STEP 1 and SURMOUNT-1 established the effect sizes at a scale no research chemical has approached.

Tesamorelin is the exception in shape: its Grade A is specifically for visceral adipose tissue in HIV-associated lipodystrophy — a defined population and a defined fat depot. For general fat loss outside that indication it is graded U, which is a useful reminder that a grade attaches to an outcome and a population, not to a molecule.

What about the compounds actually sold as fat-loss peptides?

Each has a real mechanistic story and no human fat-loss result.

AOD-9604 — a growth-hormone fragment trialled for obesity in over 500 adults. The Phase IIb result is the part the marketing omits.

Adipotide — targeted the blood supply of fat tissue and reduced fat in obese monkeys, published in Science Translational Medicine. Human development ended over kidney toxicity. It is the clearest illustration in the category that “worked in primates” and “usable in people” are different claims.

5-Amino-1MQ — a clean NNMT-inhibition mechanism, real rodent data, and zero published human efficacy trials.

MOTS-c — genuinely interesting mitochondrial biology in cells and rodents, graded D, no controlled human evidence.

SLU-PP-332 — an ERR-alpha agonist that mimics endurance training in mice. No human data at all.

Why do GH secretagogues keep appearing on these lists?

Because raising growth hormone is associated with lipolysis, and that association gets sold as a fat-loss mechanism.

The grades say otherwise. CJC-1295 and ipamorelin are graded U for fat loss and body composition; GHRP-2 and GHRP-6 are graded E — the evidence actively fails to support the claim. Raising a hormone is a measurement, and fat loss is an outcome, and the step between them is where this category consistently fails. The same pattern holds for muscle growth.

Frequently asked questions

What is the best peptide for fat loss?

On graded evidence, semaglutide and tirzepatide — both FDA-approved medications requiring a prescription, not research chemicals. No research-chemical peptide has demonstrated fat loss in controlled human trials.

Do fat loss peptides actually work?

The approved GLP-1 medications do, with large trials behind them. The compounds marketed specifically as “fat loss peptides” — AOD-9604, 5-Amino-1MQ, MOTS-c, SLU-PP-332 — do not have human evidence supporting a fat-loss effect.

Is AOD-9604 effective for weight loss?

It was trialled for obesity in over 500 adults and did not deliver. It remains widely sold on the research-chemical market regardless.

Are fat loss peptides safe?

Safety and efficacy are separate questions, and for unapproved compounds neither is established. Adipotide is the cautionary case: real fat reduction in monkeys, and a human programme ended over kidney toxicity.

Can peptides target belly fat specifically?

Tesamorelin is the one compound with Grade A evidence for a specific fat depot — visceral fat, in HIV-associated lipodystrophy. That does not generalise to abdominal fat in the general population, where it is graded U.

Why are GLP-1 drugs not called peptides?

They are peptides. Semaglutide and liraglutide are peptide molecules; tirzepatide is a dual agonist peptide. The distinction people are reaching for is approved medication versus research chemical, not peptide versus non-peptide.

The takeaway

The category splits along a line that the marketing deliberately blurs. Four peptides carry Grade A evidence for fat loss, and all four are approved medications with large trials behind them. The compounds sold as fat-loss peptides sit at the other end of the scale — unknown, unsupported, failed in trials, or never tested in humans at all.

The mechanisms are frequently real. AOD-9604 targets a genuine pathway, adipotide worked in primates, NNMT inhibition is a legitimate metabolic target. What is missing in every case is the human result, and in adipotide’s case what arrived instead was kidney toxicity.

If the question is which peptide causes fat loss, the honest answer is the one that requires a prescription and a conversation with a clinician.